Next-Generation Sequencing Stays Ahead of the Market Curve

Next-Generation Sequencing Stays Ahead of the Market Curve

The impact of genetic sequencing on life sciences research, biotechnology and medicine is unprecedented. In 25 years, genomic knowledge has been built on a staggering scale: first enabled with the innovation and commercialization of Sanger sequencing, pieced together in coordinated efforts between various institutes, and then tremendously accelerated with the introduction of higher-throughput next-generation sequencing (NGS) technologies. Sequencing remains a dynamic space that has escaped market decline presaged by ebbs in public funding and the culmination of monolithic, high-profile research projects.

For much of their market lifetime, sequencing tools were overwhelmingly purchased by institutions and actors involved in basic research such as government health institutes, universities, and non-profit research centers. The Human Genome Project and similarly profound genetic research projects were accomplished through scale or the proliferation of sequencer bases among collaborators. The conclusion of such projects and inconsistency in public funding supported forecasts of weakened demand for new NGS platforms or additional capacity build-up. Recent market results have suggested otherwise as translational research has attracted new end user groups, some newly able to perform sequencing outside of its traditional milieu due to major improvements to the technology.

Next-generation sequencing has short-circuited the translational research paradigm by serving both as a tool for the discovery and development of diagnostics and therapeutics and as a clinical diagnostics instrument itself. Next-generation sequencing has been central in the progression from programmatic, foundational basic research to diversified applied research exploring targeted and differentiated populations and sample sets. Compared to traditional Sanger sequencing, NGS dramatically improves throughput (faster turnaround times and greater lab productivity), reduces sample requirements (amount of DNA), and can be completed at a lower cost. These advantages have placed NGS at the forefront of discoveries related to disease manifestation and genetic mutation or gene expression. Low-cost, rapid sequencing has also made sequencing accessible to smaller labs.

Growth is not expected to abate dramatically anytime soon for the NGS market - Kalorama Information expects it to grow with continued demand from core end user groups, but especially from relatively green field end user groups such as hospitals, clinical labs, and private sector research and development (R&D) departments such as in pharmaceuticals.

Kalorama Information offers an updated analysis of the global NGS market with Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends). Another title, Next Generation Sequencing in Latin America dives into an emerging regional market for NGS platforms.